Fig. 1. Gavo-cel construct and CONSORT diagram.

a, Schematic diagram of gavo-cel. The patient’s autologous T cells are transduced with lentivirus carrying a plasmid encoding for an anti-mesothelin, llama-derived, single-domain antibody (MH1) fused to the CD3ε subunit using a linker sequence. Upon translation, the gavo-cel transgene integrates into the native TCR complex, exploiting the native TCR-driven T cell activation, effector function and regulation. b, CONSORT diagram showing patients enrolled and treated at different DLs. ^* Without lymphodepletion; ^a ITT patient population—patients who signed informed consent and underwent leukapheresis with the intent to receive gavo-cel as part of the phase 1 portion of the study; ^{^} Split dose of 1 × 10⁸ and 2 × 10⁸ cells on days 0 and 3. MSLN, mesothelin.